Lymphoma Hub shared a post on X:
”Congress/SOHO24/POSTER.
Jan Burger from MD Anderson Cancer Center reports 10-year analysis from RESONATE-2 study. First-line ibrutinib continues to show survival benefit in older adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) including those with the high risk genomic clinical features. The 9-year progression-free survival (PFS) and overall survival (OS) were 49.7% and 68.0%. No new safety signals were observed.”
Source: Lymphoma Hub/X
Jan Burger, M.D., Ph.D., is a Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. His research focuses on targeting the interaction between malignant B lymphocytes and the tissue microenvironment, which leukemia and lymphoma cells use for growth and survival. Specializing in chronic lymphocytic leukemia (CLL), he studies B cell receptor (BCR) signaling and the role of nurse-like macrophages (NLC) in CLL biology.
